Evidence map›Paper›PMID 28883731›Full record

ReviewNeuropsychiatric disease and treatment2017

Antipsychotic-associated weight gain: management strategies and impact on treatment adherence.

Madhubhashinee Dayabandara, Raveen Hanwella, Suhashini Ratnatunga, Sudarshi Seneviratne, Chathurie Suraweera, Varuni A de Silva

2 registry-linked trialsOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropsychiatric disease and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 167 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
167citing papers in PubMed, 15 pooled it
11.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05866107 narecruitingnot on this mapstarted 2023, after this paper: background citation

Effectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals With Mental Disorders Using Digital Intervention ("SWIM" Trial)

TypeinterventionalSponsorCapital Medical UniversityRan2023 to 2025Enrolled204ConditionsSchizophrenia, Bipolar Disorder, Metabolic Syndrome, Overweight and ObesityArmsEffectiveness and Feasibility of Self-Monitoring for Weight Management in Individuals with Mental Disorders Using Digital Intervention ("SWIM" trial)
NCT07342764 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial

TypeinterventionalSponsorSultan Qaboos UniversityRan2026 to 2028Enrolled110ConditionsAntipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight GainArmsDapagliflozin, Metformin, Common Lifestyle Program
3 · Its place in the literature

Who cites it

167 citing papers in PubMed, 15 syntheses or guidelines pooled it, 340 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. EPA guidance on lifestyle interventions for adults with severe mental illness: A meta-review of the evidence.European psychiatry : the journal of the Association of European Psychiatrists · 2024
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

107 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Madhubhashinee DayabandaraDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Raveen HanwellaDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Suhashini RatnatungaDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Sudarshi SeneviratneDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Chathurie SuraweeraDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
Varuni A de SilvaDepartment of Psychiatry, Faculty of Medicine, University of Colombo, Colombo, Sri Lanka.
University of Colombo · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antipsychotic-induced weight gain is a major management problem for clinicians. It has been shown that weight gain and obesity lead to increased cardiovascular and cerebrovascular morbidity and mortality, reduced quality of life and poor drug compliance. This narrative review discusses the propensity of various antipsychotics to cause weight gain, the pharmacologic and nonpharmacologic interventions available to counteract this effect and its impact on adherence. Most antipsychotics cause weight gain. The risk appears to be highest with olanzapine and clozapine. Weight increases rapidly in the initial period after starting antipsychotics. Patients continue to gain weight in the long term. Children appear to be particularly vulnerable to antipsychotic-induced weight gain. Tailoring antipsychotics according to the needs of the individual and close monitoring of weight and other metabolic parameters are the best preventive strategies at the outset. Switching to an agent with lesser tendency to cause weight gain is an option, but carries the risk of relapse of the illness. Nonpharmacologic interventions of dietary counseling, exercise programs and cognitive and behavioral strategies appear to be equally effective in individual and group therapy formats. Both nonpharmacologic prevention and intervention strategies have shown modest effects on weight. Multiple compounds have been investigated as add-on medications to cause weight loss. Metformin has the best evidence in this respect. Burden of side effects needs to be considered when prescribing weight loss medications. There is no strong evidence to recommend routine prescription of add-on medication for weight reduction. Heterogeneity of study methodologies and other confounders such as lifestyle, genetic and illness factors make interpretation of data difficult.

Indexed as

antipsychoticsmetabolictreatment adherenceweight gainweight-reducing agents

Identifiers

PMID28883731
PMCPMC5574691
OpenAlexW2746379998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.